secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2022-07-18T23:59:59+00:00
Accession:  0001178913-22-002674
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio appoints Miranda Toledano CEO, Dana Yaacov-Garbeli CFO; former CEO Jamas departs with $411K
--------------------------------------------------------------------------------

- Appointed Miranda Toledano as CEO effective July 15, 2022; she had served as CBO/CFO and director since 2018.
- Toledano's amended employment: annual employer cost $380K, bonus eligibility 60% of base salary, option grant of 600K shares at $1.40.
- Additional performance milestone options for 200K shares under long-term incentive.
- Dana Yaacov-Garbeli promoted to CFO effective July 15; she was Israel-based CFO since June 2019.
- Former CEO Spiros Jamas receives lump sum $411,666.67 (13 months salary) and extension of vested option exercise period for 492,832 shares for two years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/0001178913-22-002674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322002674/zk2228138.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-002674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer